Bedoukian   RussellIPM   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Alphascents
Pherobio
InsectScience
E-Econex
Counterpart-Semiochemicals
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous AbstractDecline in male mouse pheromone with age    Next AbstractIn situ analysis of solvents on breath and blood: a selected ion flow tube mass spectrometric study »

BMC Public Health


Title:Improving on estimates of the potential relative harm to health from using modern ENDS (vaping) compared to tobacco smoking
Author(s):Wilson N; Summers JA; Ait Ouakrim D; Hoek J; Edwards R; Blakely T;
Address:"University of Otago, Wellington, New Zealand. nick.wilson@otago.ac.nz. University of Otago, Wellington, New Zealand. Population Interventions, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia"
Journal Title:BMC Public Health
Year:2021
Volume:20211108
Issue:1
Page Number:2038 -
DOI: 10.1186/s12889-021-12103-x
ISSN/ISBN:1471-2458 (Electronic) 1471-2458 (Linking)
Abstract:"BACKGROUND: Although the harm to health from electronic nicotine delivery systems (ENDS) compared to smoked tobacco remains highly uncertain, society and governments still need to know the likely range of the relative harm to inform regulatory policies for ENDS and smoking. METHODS: We identified biomarkers with specificity of association with different disease groupings e.g., volatile organic compound (VOCs) for chronic obstructive pulmonary disease; and tobacco-specific N -nitrosamines (TSNAs) and polycyclic aromatic hydrocarbons (PAHs) for all cancers. We conducted a review of recent studies (post January 2017) that compared these biomarkers between people exclusively using ENDS and those exclusively smoking tobacco. The percentage differences in these biomarkers, weighted by study size and adjusted for acrolein from other sources, were used as a proxy for the assumed percentage difference in disease harm between ENDS and smoking. These relative differences were applied to previously modelled estimates of smoking-related health loss (in health-adjusted life-years; HALYs). RESULTS: The respective relative biomarker levels (ENDS vs smoking) were: 28% for respiratory diseases (five results, three studies); 42% for cancers (five results, four studies); and 35% for cardiovascular (seven results, four studies). When integrated with the HALY impacts by disease, the overall harm to health from ENDS was estimated to be 33% that of smoking. CONCLUSIONS: This analysis, suggests that the use of modern ENDS devices (vaping) could be a third as harmful to health as smoking in a high-income country setting. But this estimate is based on a limited number of biomarker studies and is best be considered a likely upper level of ENDS risk given potential biases in our method (i.e., the biomarkers used being correlated with more unaccounted for toxicants in smoking compared to with using ENDS)"
Keywords:*Electronic Nicotine Delivery Systems Healthy Life Expectancy Humans Tobacco Smoking Tobacco Use Cessation Devices *Vaping Biomarkers Electronic nicotine delivery systems Relative harm Smoking Vaping;
Notes:"MedlineWilson, Nick Summers, Jennifer A Ait Ouakrim, Driss Hoek, Janet Edwards, Richard Blakely, Tony eng Research Support, Non-U.S. Gov't Review England 2021/11/10 BMC Public Health. 2021 Nov 8; 21(1):2038. doi: 10.1186/s12889-021-12103-x"

 
Back to top
 
Citation: El-Sayed AM 2024. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2024 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 22-11-2024